To assess the antiproliferative effects of enzalutamide in different doses, alone or in combination with USP14 specific inhibitor IU1 [31] on breast cancer cells, we used an MTS assay to test cell viability on a panel of 5 breast cancer cell lines. Here, USP14 is linked to breast cancer.